Business Wire

Hillstone Networks Raises the Bar with Integrative Cybersecurity

Share

Hillstone Networks, a leading provider of cybersecurity solutions, has announced a new approach to helping customers achieve cyber resilience with integrative cybersecurity solutions that address the gaps in security and challenges faced by CISOs and security professionals. This integrative approach brings coverage, control, and consolidation to protect global enterprises from multilayer, multistage cyberattacks.

“Digital transformation is a priority for every company, and a challenge for every IT organization, as data drives the business and is now generated, processed, and analyzed everywhere – in the datacenter, on the edge, in one or multiple clouds,” states Tim Liu, CTO and Co-founder at Hillstone Networks. “Today’s CISOs are facing challenges from every direction as they address a rapidly evolving infrastructure, a fast-changing threat landscape, and increasing complexity and costs. Our approach delivers a streamlined, centralized, and scalable platform to help CISOs enhance their organization’s cyber resilience and protect critical assets.”

Hillstone Networks’ integrative cybersecurity approach tackles cybersecurity head-on in three critical areas: securing the networks, mitigating the threats, and protecting the workloads. This approach is continuously enhanced through unwavering commitment to innovation and new product releases.

Secure the Networks: Zero Trust Starts Here

Hillstone Networks' Future-ready Network Security solutions provide a strong foundation for zero-trust architecture, delivering adaptive security that can scale as business demands.

For hyperscale data centers, the newly announced Hillstone X25812 Data Center Firewall delivers high availability and high scalability with a up to 3.5 Tbps firewall throughput, 720 million concurrent connections, and 19 million new sessions per second. It comes with robust security features and advanced network capabilities for large enterprises, Carriers, and ISPs, while maintaining energy efficiency and reducing carbon footprint.

Mitigate the Threats: Before they attack you

Hillstone’s AI-powered Threat Detection and Response can find and mitigate attacks before they have a chance to exploit the most vital asset in the enterprise – data.

Hillstone Networks Breach Detection System (BDS) is at the forefront of this effort, with the recent release of version 3.7 offering expanded functionality to better protect against network attacks and threats. It supports the MITRE ATT&CK framework to improve threat detection, automate asset discovery, and deepen its integration with the Hillstone iSource XDR solution for unified threat management.

Protect the Workloads: Wherever they run

Hillstone’s Uncompromising Cloud Workload Protection solutions ensure an enterprise’s data environment and workload are fully secure.

With granular network micro-segmentation and patented traffic steering technology, Hillstone’s latest version of CloudArmour is upgraded with powerful anti-virus capability that delivers enhanced threat protection and deeper visibility into cloud workloads, so that organizations can embrace a cyber-resilient cloud infrastructure.

To learn more about Hillstone Networks’ Integrative Cyber Security solutions, visit the Hillstone experts during RSAC 2023, at #1155 Moscone South, in San Francisco, from April 24th – April 27th.

About Hillstone Networks

Hillstone Networks is a leader in cybersecurity, delivering both depth and breadth of protection to companies of all sizes, from edge to cloud, and across any workload. Hillstone Networks’ Integrative Cyber Security approach brings coverage, control, and consolidation to more than 26,000 enterprises worldwide. www.hillstonenet.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Contact
Zeyao Hu
+1 4085086750
inquiry@hillstonenet.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release

Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release

Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release

Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r

Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye